🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Researchers develop blood test to gauge Alzheimer's risk

Published 01/02/2018, 07:08 pm
Updated 01/02/2018, 07:10 pm
© Reuters.  Researchers develop blood test to gauge Alzheimer's risk

TOKYO/MELBOURNE, Feb 1 (Reuters) - Researchers in Japan and Australia have developed a blood test that detects the toxic protein amyloid beta which has been linked to Alzheimer's brain disease.

The joint study published in the scientific journal Nature on Wednesday said the test was more than 90 percent accurate.

The study was based on 252 Australian and 121 Japanese patients aged 60 to 90 years of age, some classed as cognitively normal, others with mild cognitive impairment and some with Alzheimer's.

The blood test opens the way for possibly far cheaper and less invasive tests for amyloid beta, which builds up in the brain as Alzheimer's develops, said the researchers.

Currently brain scans or invasive cerebrospinal fluid testing, also known as a spinal tap, are used to ascertain the deposition in the brain of an abnormal protein, called amyloid beta. Some brain imaging tests can cost more than 150,000 yen ($915).

A simple, low-cost blood tests could also make it easier for pharmaceutical companies to secure enough people at risk of Alzheimer's to test new drugs to fight the disease, said researchers.

"Our blood test may ... have a transformative potential to facilitate the development of effective drugs for Alzheimer's disease," Katsuhiko Yanagisawa, director-general of the Japanese National Center for Geriatrics and Gerontology's research institute, said in a statement.

University of Melbourne Professor Colin Masters, a member of the Australian team of researchers, said the blood test was a step towards a potential cure for the disease.

"You have got to walk before you run. You have to learn to diagnose the disease directly before you can hope to see the effect of therapeutic intervention. And that's where the real value in this test will come," Masters said.

Alzheimer's disease starts years before patients have any symptoms of memory loss, so the key to treatment is in early detection.

Alzheimer's disease is the most common form of dementia, affecting up to 70 percent of all people with dementia, with three in 10 people over 85 having dementia, according to the Australian government's Dementia Australia organisation.

The disease was first recorded in 1907 by Dr Alois Alzheimer. ($1 = 109.3400 yen)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.